Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate

OBJECTIVES: U-Act-Early was a 2-year, randomized placebo controlled, double-blind trial, in which DMARD-naïve early RA patients were treated to the target of sustained remission (SR). Two strategies initiating tocilizumab (TCZ), with and without methotrexate (MTX), were more effective than a strateg...

Descripción completa

Detalles Bibliográficos
Autores principales: Verhoeven, Maxime M A, Tekstra, Janneke, Welsing, Paco M J, Pethö-Schramm, Attila, Borm, Michelle E A, Bruyn, George A W, Bos, Reinhard, Griep, Ed N, Klaasen, Ruth, van Laar, Jacob M, Lafeber, Floris P J G, Bijlsma, Johannes W J, de Hair, Marjolein J H, Jacobs, Johannes W G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449801/
https://www.ncbi.nlm.nih.gov/pubmed/31859346
http://dx.doi.org/10.1093/rheumatology/kez602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449801/
https://www.ncbi.nlm.nih.gov/pubmed/31859346
http://dx.doi.org/10.1093/rheumatology/kez602

Ejemplares similares